Memantine (Namenda) for moderate to severe Alzheimer's disease

被引：0
|
作者：
Ables, AZ [1 ]
机构：
[1] Spartanburg Family Med Residency Program, Spartanburg, SC USA
来源：
AMERICAN FAMILY PHYSICIAN | 2004年 / 69卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
Synopsis: Memantine (Namenda) is an N-methyl-d-aspartate'(NMDA) receptor blocker indicated for the treatment of moderate to severe Alzheimer's disease (AD). The NMDA receptor is activated by glutamate, the primary excitatory neurotransmitter in the brain. Overstimulation by glutamate may result in neuronal damage and has been implicated in neurodegenerative disorders such as AD. Memantine is the first pharmacologic agent approved by the US. Food and Drug Administration for the treatment of moderate to severe AD.
引用
收藏
页码：1491 / 1492
页数：2
相关论文
共 50 条
  • [41] Resource Utilisation and Cost Analysis of Memantine in Patients with Moderate to Severe Alzheimer’s Disease
    Anders Wimo
    Bengt Winblad
    Albrecht Stöffler
    Yvonne Wirth
    Hans-Jörg Möbius
    PharmacoEconomics, 2003, 21 : 327 - 340
  • [42] Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer's disease
    Emre, Murat
    Mecocci, Patrizia
    Stender, Karina
    JOURNAL OF ALZHEIMERS DISEASE, 2008, 14 (02) : 193 - 199
  • [43] Memantine - A pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease
    Plosker, GL
    Lyseng-Williamson, KA
    PHARMACOECONOMICS, 2005, 23 (02) : 193 - 206
  • [44] Specific benefits of memantine on behavioural symptoms in patients with moderate to severe Alzheimer's disease
    Gauthier, S.
    Cooper, J.
    Loft, H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 : 65 - 65
  • [45] Memantine for moderate and severe Alzheimer's disease: systematic review and meta-analysis
    Minakaran, N.
    McShane, R.
    Sastre, A. Areosa
    EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 : 34 - 34
  • [46] Specific benefits of memantine on behavioural symptoms in patients with moderate to severe Alzheimer's disease
    Cummings, J.
    Gauthier, S.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 : S528 - S529
  • [47] Memantine and individual activities of daily living in moderate to severe Alzheimer's disease.
    Feldman, H
    Schmitt, F
    Doraiswamy, P
    Graham, SM
    Bell, JM
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2005, 53 (04) : S26 - S26
  • [48] Memantine in moderate to severe Alzheimer’s disease: an observational post-marketing study
    Michael Rainer
    A. Wuschitz
    C. Jagsch
    C. Erb
    J.-J. Chirikdjian
    H. A. M. Mucke
    Journal of Neural Transmission , 2011, 118
  • [49] Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease
    Wimo, A
    Winblad, B
    Stoffler, A
    Wirth, Y
    Möbius, HJ
    PHARMACOECONOMICS, 2003, 21 (05) : 327 - 340
  • [50] Memantine treatment is beneficial for functional capacities of patients with moderate to severe Alzheimer's disease
    Wirth, Y
    Doody, RS
    Schmitt, FA
    Möbius, HJ
    Stöffler, A
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S207 - S207
12345